Co-delivery of Diverse Therapeutic Compounds Using PEG–PLGA Nanoparticle Cargo against Drug-Resistant Bacteria: An Improved Anti-biofilm Strategy

Deepika, M; Thangam, Ramar; Kannan, R.; Sheena, Thankaraj Salammal; Srinivasan, Sivasubramanian; Jeganathan, K.; Ramasamy, Thirumurugan

doi:10.1021/acsabm.9b00850

Cited by 37 publications

(21 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After incubating the plates with the staining solution, the plates were washed with PBS three times. Images were obtained using a fluorescence microscope (Accu Scope EXI-310) at a magnification of ×20 (Mohamed Subarkhan et al., 2016 ; Balaji et al., 2020 ; Deepika et al., 2020 ).…”

Section: Methodsmentioning

confidence: 99%

Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

Xiao

Gao

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Gastric cancer is a frequently occurring cancer with high mortality each year worldwide. Finding new and effective therapeutic strategy against human gastric cancer is still urgently required. Hence, we have established a new method to achieve treatment-actuated modifications in a tumor microenvironment by utilizing synergistic activity between two potential anticancer drugs. Dual drug delivery of gemcitabine (GEM) and Camptothecin-11 (CPT-11) exhibits a great anti-cancer potential, as GEM enhances the effect of CPT-11 treatment of human gastric cells by providing microenvironment stability. However, encapsulation of GEM and CPT-11 obsessed by poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs) is incompetent owing to unsuitability between the binary free GEM and CPT-11 moieties and the polymeric system. Now, we display that CPT-11 can be prepared by hydrophobic covering of the drug centers with dioleoylphosphatidic acid (DOPA). The DOPA-covered CPT-11 can be co-encapsulated in PLGA NPs alongside GEM to stimulate excellent anticancer property. The occurrence of the CPT-11 suggestively enhanced the encapsulations of GEM into PLGA NPs (GEM-CPT-11 NPs). Formation of the nanocomposite (GEM-CPT-11 NPs) was confirmed by FTIR and X-ray spectroscopic techniques. Further, the morphology of GEM NPs, CPT-11 NPs, and GEM-CPT-11 NPs and NP size was examined by transmission electron microscopy (TEM), respectively. Furthermore, GEM-CPT-11 NPs induced significant apoptosis in human gastric NCI-N87 and SGC-791 cancer cells in vitro. The morphological observation and apoptosis were confirmed by the various biochemical assays (AO-EB, nuclear staining, and annexin V-FITC). In addition, evaluation of the hemolysis assay with erythrocytes of human shows excellent biocompatibility of free GEM, free CPT-11, GEM NPs, CPT-11 NPs, and GEM-CPT-11 NPs. The results suggest that GEM-CPT-11 NPs are one of the promising nursing cares for human gastric cancer therapeutic candidates worthy of further investigations.

show abstract

Section: Methodsmentioning

confidence: 99%

Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

Xiao

Gao

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Drugs loaded on these systems had improved biocompatibility and bio-activity. Drug-loaded PLGA-NPs exhibited higher antibacterial activity compared to the drugs alone or the unloaded NPs [97,98]. Chitosan NPs enhanced the delivery and efficacy of HIV-1 P24 protein-derived peptides [99].…”

Section: Nps With Antimicrobial Activity and Their Mode Of Actionmentioning

confidence: 99%

Nanotechnology-Based Delivery Systems for Antimicrobial Peptides

et al. 2021

View full text Add to dashboard Cite

Antimicrobial resistance (AMR) is a significant threat to global health. The conventional antibiotic pool has been depleted, forcing the investigation of novel and alternative antimicrobial strategies. Antimicrobial peptides (AMPs) have shown potential as alternative diagnostic and therapeutic agents in biomedical applications. To date, over 3000 AMPs have been identified, but only a fraction of these have been approved for clinical trials. Their clinical applications are limited to topical application due to their systemic toxicity, susceptibility to protease degradation, short half-life, and rapid renal clearance. To circumvent these challenges and improve AMP’s efficacy, different approaches such as peptide chemical modifications and the development of AMP delivery systems have been employed. Nanomaterials have been shown to improve the activity of antimicrobial drugs by providing support and synergistic effect against pathogenic microbes. This paper describes the role of nanotechnology in the targeted delivery of AMPs, and some of the nano-based delivery strategies for AMPs are discussed with a clear focus on metallic nanoparticle (MNP) formulations.

show abstract

“…For instance, Ucak et al investigated the antibacterial effect of teicoplanin-containing PLGA nanoparticles functionalized with S. aureus -specific aptamers [ 130 ]. Moreover, Deepika et al synthesized PEG–PLGA nanoparticles for the co-delivery of rutin, a natural drug, and benzamide, a synthetic compound [ 131 ]. Alternatively, Durak et al studied the effects of PLGA NPs containing natural biocompounds known for their antibacterial activities, namely caffeic acid and juglone [ 132 ].…”

Section: Antimicrobial Applications Of Polymeric Nanoparticlesmentioning

confidence: 99%

Polymeric Nanoparticles for Antimicrobial Therapies: An up-to-date Overview

et al. 2021

View full text Add to dashboard Cite

Despite the many advancements in the pharmaceutical and medical fields and the development of numerous antimicrobial drugs aimed to suppress and destroy pathogenic microorganisms, infectious diseases still represent a major health threat affecting millions of lives daily. In addition to the limitations of antimicrobial drugs associated with low transportation rate, water solubility, oral bioavailability and stability, inefficient drug targeting, considerable toxicity, and limited patient compliance, the major cause for their inefficiency is the antimicrobial resistance of microorganisms. In this context, the risk of a pre-antibiotic era is a real possibility. For this reason, the research focus has shifted toward the discovery and development of novel and alternative antimicrobial agents that could overcome the challenges associated with conventional drugs. Nanotechnology is a possible alternative, as there is significant evidence of the broad-spectrum antimicrobial activity of nanomaterials and nanoparticles in particular. Moreover, owing to their considerable advantages regarding their efficient cargo dissolving, entrapment, encapsulation, or surface attachment, the possibility of forming antimicrobial groups for specific targeting and destruction, biocompatibility and biodegradability, low toxicity, and synergistic therapy, polymeric nanoparticles have received considerable attention as potential antimicrobial drug delivery agents. In this context, the aim of this paper is to provide an up-to-date overview of the most recent studies investigating polymeric nanoparticles designed for antimicrobial therapies, describing both their targeting strategies and their effects.

show abstract

Co-delivery of Diverse Therapeutic Compounds Using PEG–PLGA Nanoparticle Cargo against Drug-Resistant Bacteria: An Improved Anti-biofilm Strategy

Cited by 37 publications

References 64 publications

Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

Nanotechnology-Based Delivery Systems for Antimicrobial Peptides

Polymeric Nanoparticles for Antimicrobial Therapies: An up-to-date Overview

Contact Info

Product

Resources

About